Echtzeit-Aktienkurs Acceleron Pharma Inc.
Bid:
Ask:
Echtzeit-Chart der Acceleron Pharma Inc. Aktie
Fundamentaldaten der Acceleron Pharma Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2020 [USD] | 92,52 Mio. | -166,01 Mio. | -166,03 Mio. | -2,92 | - | - | - |
| 2019 [USD] | 73,99 Mio. | -124,92 Mio. | -124,86 Mio. | -2,38 | - | - | - |
| 2018 [USD] | 13,99 Mio. | -118,90 Mio. | -118,87 Mio. | -2,59 | - | - | - |
| 2017 [USD] | 13,48 Mio. | -108,42 Mio. | -108,45 Mio. | -2,68 | - | - | - |
| 2016 [USD] | 27,77 Mio. | -56,99 Mio. | -57,01 Mio. | -1,52 | - | - | - |
| 2015 [USD] | 18,10 Mio. | -63,89 Mio. | -63,89 Mio. | -1,92 | - | - | - |
| 2014 [USD] | 14,63 Mio. | -51,26 Mio. | -51,26 Mio. | -1,63 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Acceleron Pharma Inc. Aktie
Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neurom